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Abstract
Background: Glomerular filtration rate (GFR) and urinary albumin excretion (UAE) are markers
of kidney function that are known to be heritable. Many endocrine conditions have strong familial
components. We tested for association between the Affymetrix GeneChip Human Mapping 100K
single nucleotide polymorphism (SNP) set and measures of kidney function and endocrine traits.
Methods: Genotype information on the Affymetrix GeneChip Human Mapping 100K SNP set was
available on 1345 participants. Serum creatinine and cystatin-C (cysC; n = 981) were measured at
the seventh examination cycle (1998–2001); GFR (n = 1010) was estimated via the Modification of
Diet in Renal Disease (MDRD) equation; UAE was measured on spot urine samples during the sixth
examination cycle (1995–1998) and was indexed to urinary creatinine (n = 822). Thyroid
stimulating hormone (TSH) was measured at the third and fourth examination cycles (1981–1984;
1984–1987) and mean value of the measurements were used (n = 810). Age-sex-adjusted and
multivariable-adjusted residuals for these measurements were used in association with genotype
data using generalized estimating equations (GEE) and family-based association tests (FBAT)
models. We presented the results for association tests using additive allele model. We evaluated
associations with 70,987 SNPs on autosomes with minor allele frequencies of at least 0.10, Hardy-
Weinberg Equilibrium p-value ≥ 0.001, and call rates of at least 80%.
Results: The top SNPs associated with these traits using the GEE method were rs2839235 with
GFR (p-value 1.6*10-05), rs1158167 with cysC (p-value 8.5*10-09), rs1712790 with UAE (p-value
1.9*10-06), and rs6977660 with TSH (p-value 3.7*10-06), respectively. The top SNPs associated with
these traits using the FBAT method were rs6434804 with GFR(p-value 2.4*10-5), rs563754 with
cysC (p-value 4.7*10-5), rs1243400 with UAE (p-value 4.8*10-6), and rs4128956 with TSH (p-value
3.6*10-5), respectively. Detailed association test results can be found at http://
www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?id=phs000007. Four SNPs in or near the CST3
gene were highly associated with cysC levels (p-value 8.5*10-09 to 0.007).
Published: 19 September 2007
BMC Medical Genetics 2007, 8(Suppl 1):S10 doi:10.1186/1471-2350-8-S1-S10
<supplement> <title> <p>The Framingham Heart Study 100,000 single nucleotide polymorphisms resource</p> </title> <editor>Emelia J Benjamin, Caroline S Fox, Daniel J Gottlieb, Cashell E Jaquish, Daniel Levy, James B Meigs, Christopher Newton-Cheh, Christopher J O'Donnell and Ramachandran  S Vasan</editor> <note>Research</note> <url>http://www.biomedcentral.com/content/pdf/1471-2350-8-S1-info.pdf</url> </supplement>
This article is available from: http://www.biomedcentral.com/1471-2350/8/S1/S10
© 2007 Hwang et al; licensee BioMed Central Ltd. 
This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.BMC Medical Genetics 2007, 8(Suppl 1):S10 http://www.biomedcentral.com/1471-2350/8/S1/S10
Page 2 of 10
(page number not for citation purposes)
Conclusion:  Kidney function traits and TSH are associated with SNPs on the Affymetrix
GeneChip Human Mapping 100K SNP set. These data will serve as a valuable resource for
replication as more SNPs associated with kidney function and endocrine traits are identified.
Background
Kidney disease affects 19 million adults in the United
States [1]. Chronic kidney disease (CKD) is associated
with cardiovascular disease [2-4], stroke [5], peripheral
arterial disease [5,6], and all-cause mortality [7,8]. CVD
risk factors are associated with the development of kidney
disease [9], and the prevalence of traditional and novel
CVD risk factors is elevated among those with kidney dis-
ease [7,10]. Urinary albumin excretion (UAE) is an early
marker of kidney function that predicts CKD progression
[11-14]. While glomerular filtration rate (GFR) and UAE
are both measurements for kidney function, they repre-
sent different phenotypes and identify different subsets of
at-risk individuals [15].
Genetic factors play a role in the progression of renal dis-
ease. Familial aggregation of end-stage renal disease has
been identified [16]. Linkage analyses of kidney function
have been conducted [17-21], and novel loci have been
mapped to chromosomes 1 [18], 2 [21,22], 3 [17], 7 [22],
10 [19,20,22], and 18 [22]. In the Framingham Heart
Study, we have shown that kidney function is heritable
[23], suggesting a role for genetic mechanisms in its etiol-
ogy. Results of the linkage study from the Framingham
Heart Study suggested linkage between kidney disease and
a locus on chromosome 4 with a LOD score of 2.2 [23].
Familial clustering of UAE has been observed in siblings
of subjects with diabetes [24], and UAE has been shown
to be heritable among the offspring of diabetic subjects
[25]. Genome-wide linkage analyses have mapped novel
loci to chromosomes 12 [26] and 19 [26] among families
enriched for hypertension. Among families with more
severe forms of nephropathy, suggestive evidence for link-
age has been found on chromosome 10p [27] and 9q31–
32 [28]. In the Framingham Heart Study, we observed a
LOD score of 2.2 for UAE on chromosome 8 [29].
Thyroid disease, including Hashimoto's thyroiditis and
Graves' disease, has a known familial component [30],
and the same genes may underlie both conditions [31].
Measures of thyroid function have been shown to be her-
itable [32-34], and linkage has been reported to chromo-
some 18 for autoimmune thyroid disease in at least 2
studies [35,36].
As part of the Framingham Heart Study 100K Project, we
sought to test the relation of multiple kidney and endo-
crine traits to 70,987 SNPs. In this manuscript, we focus
the results of association studies for GFR, UAE, cysC, and
thyroid stimulating hormone (TSH), a sensitive measure
of thyroid function.
Methods
Overall, 1345 participants were genotyped for the Affyme-
trix GeneChip Human Mapping 100K SNP set. For this
manuscript, we focused on GFR from examination 7, UAE
from examination 6, serum cysC from examination 7, and
mean TSH from examinations 3 and 4. Phenotypes were
available in 1010 participants for GFR at exam cycle 7,
822 participants for UAE at exam cycle 6, 981 participants
for cysC at exam cycle 7, and 810 participants for mean
TSH at exam cycles 3 and 4. Details about the selection
process and genotyping are provided in the Overview
[37]. Age-sex- and multivariable-adjusted residuals were
generated; we present here only the results for multivaria-
ble-adjusted traits (all available results can be found in the
website http://www.ncbi.nlm.nih.gov/projects/gap/cgi-
bin/study.cgi?id=phs000007). We evaluated associations
with 70,987 SNPs on autosomes with minor allele fre-
quencies of at least 0.10, HWE p-value ≥ 0.001, and geno-
typic call rates of at least 80%.
Phenotype assessment
Serum creatinine was measured using the modified Jaffe
method at exams 2 (1978–1981), 5 (1991–1995), 6
(1995–1998), and 7 (1998–2001), and glomerular filtra-
tion rate (GFR) was estimated using the simplified Modi-
fication of Diet in Renal Disease Study equation [38,39].
CKD was defined based on the National Kidney Founda-
tion Kidney Disease Outcome Quality Initiative working
group, and modified slightly as previously described [9].
Urinary albumin concentration (UAE) was measured by
immuno-turbidmetry (Tina-quant Albumin assay; Roche
Diagnostics, Indianapolis, IN) during the sixth examina-
tion cycle (1995–1998). Urinary albumin was indexed to
urinary creatinine (as the urine albumin/creatinine ratio,
UACR) in order to account for differences in urine con-
centration. UACR is a validated and reliable single-sample
measure of urinary albumin excretion and is highly corre-
lated with albumin excretion rates assessed by 24-h urine
collection [40,41]. Cystatin-C (cysC) was measured using
particle enhanced immunonephelometry (Dade Behring
BN 100 nephelometer; Dade Behring – Cystatin C rea-
gent) with an inter-assay and intra-assay coefficient of var-
iation of 3.3 and 2.4%, respectively. We have previously
published correlates of CKD in the Framingham Heart
Study, including hypertension, diabetes, smoking, obes-
ity, and low HDL cholesterol [9,42].BMC Medical Genetics 2007, 8(Suppl 1):S10 http://www.biomedcentral.com/1471-2350/8/S1/S10
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TSH was measured using a chemoluminescence assay
(London Diagnostics, Eden Prairie, Minn) with a lower
limit of detection of 0.01 mU/L. Luteinizing hormone
(LH), follicle stimulating hormone (FSH), and dehydroe-
piandrosterone sulfate (DHEAS) were measured as previ-
ously described [43,44]. Briefly, DHEAS concentrations
were measured on serum samples via radioimmunoassay
(Diagnostic Products Corp, CA). Calcium and phospho-
rous were measured at the second examination cycle using
a standard colorimetric method (Roche Diagnostics,
Alameda, CA), and uric acid was measured at the second
examination cycle using an autoanalyzer with a phospho-
tungstic acid reagent.
Genotyping
Genotyping was performed using the 100K Affymetrix
GeneChip. Please see the Overview [37] for details.
Statistical methods
Phenotypes used for the analysis were created by generat-
ing normalized residuals. We generated both age-sex
adjusted and multivariable adjusted residuals for each
trait. Table 1 shows the covariates included in the multi-
variable adjustment; all data in this manuscript represents
the multivariable-adjusted traits. All association analyses
were performed using the generalized estimating equa-
tions or family based association tests; details are pro-
vided in the Overview [37]. Methods to verify family
structure, generate identity-by-descent for these 1345 par-
ticipants with genotype information as well as the mark-
ers used for linkage analysis, is detailed in the Overview
[37]. To assess the clustering of significance between each
SNP and phenotypes that were repeatedly measured in
several examination cycles (see the third table in this arti-
cle), we generated the geometric mean of p-values for
SNPs that fit the following criteria: at least 4 out of 6 p-val-
ues of <0.01 in GEE or FBAT analyses for 6 GFR traits
(change in serum creatinine from exam 2 to 7; GFR at
exam 2; GFR at exam 5; GFR at exam 6; GFR at exam 7;
mean GFR exams 2, 5, 6, 7); one out of two UACR traits
(UACR; UACR in a sample enriched for hypertension);
three out of three of TSH traits (TSH at exam 3; TSH at
exam 4; mean TSH at exams 3 and 4). Among the GFR
traits, Pearson correlation coefficients ranged from 0.18
(p < 0.001) between GFR at exam 2 and exam 7, to 0.77
(p < 0.001) for the mean of GFR at exams 2, 5, 6, and 7
and GFR at exam 7. Linkage analysis was performed using
the variance components methods on a subset of 100K
markers and Marshfield short-tandem repeats; please see
the Overview [37] for more details. Partial R2, the adjusted
percentage of the phenotype variation explained by the
genotype variation, was estimated by subtracting the
adjusted R2 value for a model that excludes the genotype
from the R2 value for a model that includes the genotype.
Results
A description of all traits and phenotypes, including rele-
vant examination cycles and multivariable-adjustments, is
presented in Table 1. The median eGFR among individu-
als with CKD in our sample is 53.7 ml/min/1.73 m2.
Table 2a presents the top 25 SNPs with the lowest p-values
obtained via GEE for GFR, cysC, UAE, and mean TSH;
additional results can be found on the National Center for
Biotechnology Information website http://
www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/
study.cgi?id=phs000007. The top SNP associated with
GFR, cysC, and UAE were rs2829235 (p-value 1.6*10-05),
rs1158167 (p-value 8.5*10-09) near the cysC precursor
gene family (CST3, CST4, CST9), and rs1712790 (p-value
1.9*10-06), respectively (Table 2a). The top SNP to be
associated with mean TSH was rs6977660 (p-value
3.7*10-06). Three SNPs were not shown on Table 2a due
to the linkage disequilibrium (LD) (r2 > 0.8) with the
other top SNPs. These three SNPs were significantly asso-
ciated with UAE at exam 6: rs9305355 (p-value 2.1*10-5)
in LD with rs9305354, rs725304 (p-value 2.5*10-5) in LD
with rs723464, and rs725307 (p-value 3.2 *10-5) in LD
with rs723464. Table 2b presents the top SNPs based on
the FBAT procedure. One SNP, rs10511594 (p = 9.0*10-5)
was in LD (r2 > 0.8) with rs7865184 (p = 4.0*10-5) for
mean TSH.
Table 2c presents all traits examined with LOD scores of at
least 2.5. One locus on chromosome 1 (nearest marker on
the 100K GeneChip, rs10489578) was linked to GFR with
a LOD score of 3.08. We observed a LOD score of 4.28 for
uric acid to chromosome 2 (nearest marker rs10495487),
a location we have previously identified using Marshfield
linkage analysis to uric acid [45].
Table 3 presents the top SNPs for our multiple phenotype
analysis for GFR, UAE, and TSH with a total of 24 SNPs
showing consistently significant associations with multi-
ple related phenotypes. Tables 4a and 4b present results
looking at replication of genes that have been associated
with kidney traits in the published literature. Four SNPs in
or near the CST3 gene were highly correlated with cysC
levels (p-value 8.5*10-09 to 0.007). All four SNPs have
minor allele frequencies greater than 10% and none were
in linkage disequilibrium (defined by R2 > 0.8) as shown
on Table 4. The proportion of the cysC variation that can
be explained by these SNPs is shown in Table 4.
rs1158167 accounts for 2.5% of the cysC variation. We
found nominal significance between a SNP near the APOE
gene and CKD (p = 0.04).
Additional findings
We also identified several other plausible candidate genes
that appear in our list of top 500 SNPs for each trait (see
http://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/BMC Medical Genetics 2007, 8(Suppl 1):S10 http://www.biomedcentral.com/1471-2350/8/S1/S10
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study.cgi?id=phs000007). For GFR, we identified LRP1B
(GEE p-value = 0.0006, rs1049688), ADRBK2  (GEE p-
value = 0.002, rs1048312), APOB (GEE p-value = 0.003,
rs1048312), several genes in the chromosome 17 cytokine
gene cluster including CCL3, CCL4, and CCL18 (GEE p-
value 0.004, rs1818816), SCARB1 (GEE p-value = 0.004,
rs1902569), NFKB1 (FBAT p-value = 0.001, rs230489),
TGFB1 (FBAT p-value = 0.003, rs2072239), and PPARG
(FBAT p-value = 0.005, rs709157). For UAE, we also iden-
tified a SNP in the LRP1B gene (GEE p-value = 0.004,
rs1049687). For cysC, we identified SNPs in the LRP1B
gene (GEE p-value = 0.001, rs1463615), ANGPT1 (GEE p-
value = 0.005, rs4354281), NFKB1 (FBAT p-value = 0.004,
rs2991716), and PPARG  (FBAT p-value = 0.004,
rs1051041). For mean TSH, we identified SNPs in
ADRBK2 (GEE p-value = 0.002, rs3888397), TRHDE (GEE
p-value = 0.002, rs2044305) and DIO2 (GEE p-value =
0.003, rs54566), the SCD4 gene (rs10516679 GEE p-
value = 0.0007 FBAT p-value = 0.02), VLDLR (FBAT p-
value = 0.002, rs4084415) and APOBEC2P (FBAT p-value
= 0.005, rs722442).
Discussion
In our analysis of kidney-related traits, we have found
strong evidence for association between multiple kidney-
related traits and TSH with SNPs on the Affymetrix 100K
GeneChip. We found strong evidence for association
between cysC levels and 4 SNPs in or near the CST3 gene.
For UAE, we observed strong association with ADAM23, a
gene involved in the metalloproteinase family, which may
be involved in the pathophysiology of glomerulosclerosis
[46], and PCDH9, a gene that is a member of the cadherin
superfamily. For TSH, we observed significant association
with the HSPA4L gene with a mean p-value for all three
TSH measurements, a gene that is part of the heat shock
protein family, which may be involved in the pathophys-
iology of thyroid disease [47]. We also observed associa-
tion with the SCD4 gene, a gene involved in the
conversion of saturated to monounsaturated fatty acids;
TSH is an important correlate of lipid levels [48].
In our linkage results, we observed a region we have pre-
viously noted for uric acid [45], albeit with a significantly
higher LOD score. We identified a LOD score of 2.78 on
chromosome 3, approximately 18 Mb away from a region
previously noted in association with kidney function in
hypertensive individuals [17], a region that lies within our
1.5 support LOD interval. We also report novel loci for
GFR and TSH.
We show significant association between cysC levels and
the CST3 gene, an observation that has been previously
noted [49]. Our top SNP reaches genome-wide signifi-
cance, and may represent a true finding. In our candidate
gene approach, we found nominal significance for a SNP
near the APOE gene, a gene that has been associated with
CKD [50]. Unfortunately, poor coverage of the APOE gene
by the Affymetrix 100K Genechip precluded a more in-
depth test of association with SNPs in the APOE gene and
CKD.
Strengths of our study lie in our assessment of multiple
measures of kidney function and endocrine traits in a
sample unselected for these traits, thus reducing bias. We
Table 1: Traits names, Framingham Heart Study examination cycle, and multivariable adjustments
Trait Sample size Exam cycle/s
Offspring Original Cohort Adjustment†
Serum Creatinine 840–1010 2, 5, 6, 7 0 Age and sex; multivariable*
Change in serum creatinine 854 2, 7 0 Age and sex; multivariable*
Glomerular Filtration Rate (GFR) 840–1010 2, 5, 6, 7 0 Age and sex; multivariable*
Chronic Kidney Disease 1010 7 0 Age and sex; multivariable*
Cystatin C 981 7 0 Age and sex; multivariable*
Uric acid 912–1031 1, 2 0 Age and sex; multivariable*
Urinary Albumin Excretion 822 6 0 Age and sex; multivariable*
Urinary Albumin Excretion ≥ 30 mg/g; 
Hypertension-enriched sample
532 6 0 Age and sex; multivariable*
Serum Calcium 906 2 0 Age and sex; age, sex, serum creatinine
Serum Phosphorus 911 2 0 Age and sex; age, sex, and serum creatinine
Thyroid stimulation hormone (TSH) 883 3 0 Age and sex; age, sex, body mass index, smoking, menopausal status, thyroid 
hormone use
Mean of TSH exam 3 & 4 810 3, 4 0 Age and sex; age, sex, body mass index, smoking, menopausal status, thyroid 
hormone use
Luteinizing hormone (LH) ** 508 3 0 Age and multivariable***
Follicle stimulating hormone (FSH)** 509 3 0 Age and multivariable***
Dehydroepiandrosterone sulfate (DHEAS) 850 3 0 Age and sex; multivariable***
*Multivariable adjustment include age, sex, systolic blood pressure, hypertension treatment, HDL-cholesterol, smoking, diabetes, body mass index
**Men and post-menopausal women only with natural menopause not using hormone replacement treatment or oral contraceptive pills
*** Age, diabetes mellitus, impaired fasting glucose, smoking, systolic blood pressure, diastolic blood pressure, body-mass index, hypertension 
treatment, prevalent cardiovascular disease, total cholesterol/HDL ratio and alcohol intakeBMC Medical Genetics 2007, 8(Suppl 1):S10 http://www.biomedcentral.com/1471-2350/8/S1/S10
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Table 2: Most significant results for GFR (examination 7), UAE (examination 6), cysC (examination 7), and mean TSH (examinations 3 
and 4) by GEE (2a), FBAT (2b) and linkage (2c) analyses
2a. Top 25 SNPs for association with GFR (examination 7), UAE (examination 6), cysC (examination 7), and mean TSH (examinations 3 and 4) based 
on the lowest p value of the GEE test. Corresponding phenotype names on the web are GFRMV7 (GFR), UAELNMV6 (UAE), CYSCMV7 (CysC), and 
TSHMEAN34MV (TSH)
TRAIT SNP Physical Location (Mb) Chromosome P value – FBAT P value – GEE GENE
CysC rs1158167 23,526,189 20 0.006 8.5*10-09 CST9L|CST9|CST3
UAE rs1712790 114,126,679 11 0.014 1.9*10-06 FAM55B
TSH rs6977660 19,578,720 7 0.010 3.7*10-06
TSH rs9322817 105,338,926 6 0.502 6.5*10-06 HACE1
TSH rs10499559 21,882,699 7 0.068 8.3*10-06 RAPGEF5
UAE rs9305354 28,397,067 21 0.013 8.4*10-06
CysC rs2145231 23,573,547 20 0.011 1.1*10-05 CST9|CST3|CST4
UAE rs723464 133,940,196 4 0.000 1.1*10-05
UAE rs2113379 207,177,180 2 0.003 1.4*10-05 ADAM23
GFR rs2839235 46,625,020 21 0.055 1.6*10-05 PCNT2
TSH rs10493147 129,095,104 4 0.040 2.1*10-05 HSPA4L
TSH rs784490 39,148,534 3 0.005 2.8*10-05 TTC21A
UAE rs278021 6,698,929 1 0.958 2.9*10-05 DNAJC11
UAE rs1856190 33,598,615 9 0.127 3.0*10-05
UAE rs10485409 91,562,132 6 0.147 3.1*10-05
UAE rs2785980 216,088,914 1 4.8*10-04 3.7*10-05
UAE rs837678 191,168,583 3 0.012 3.8*10-05 LEPREL1
GFR rs3095160 49,844,269 13 0.002 3.8*10-05
UAE rs2761171 99,278,898 13 0.078 4.1*10-05 CLYBL
GFR rs10507344 24,623,069 13 0.017 4.1*10-05 PABPC3
GFR rs890945 157,924,801 5 0.036 4.7*10-05
UAE rs10502192 114,127,562 11 0.051 4.9*10-05 FAM55B
GFR rs10489639 157,492,600 1 0.194 4.9*10-05 CD48
TSH rs9308765 118,759,439 2 0.353 5.1*10-05
TSH rs3908399 12,849,275 20 8.0*10-04 5.2*10-05
2b. Top 25 SNPs for association with GFR (examination 7), UAE (examination 6), cysC (examination 7), and mean TSH (examinations 3 and 4) based 
on the lowest p-value of the FBAT test. Corresponding phenotype names on the web are GFRMV7 (GFR), UAELNMV6 (UAE), CYSCMV7 (CysC), and 
TSHMEAN34MV (TSH)
TRAIT SNP Physical Location (Mb) Chromosome P value - FBAT P value - GEE GENE
GEE GENE
UAE rs1243400 9,016,664 10 4.8*10-06 0.036
UAE rs827640 9,028,017 10 1.5*10-05 0.047BMC Medical Genetics 2007, 8(Suppl 1):S10 http://www.biomedcentral.com/1471-2350/8/S1/S10
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UAE rs7315682 32,577,224 12 2.1*10-05 0.28 FGD4
GFR rs6434804 196,589,899 2 2.4*10-05 0.003 DNAH7
UAE rs1543468 230,655,160 1 2.5*10-05 0.253 SLC35F3
UAE rs723464 133,940,196 4 2.7*10-05 1.0*10-05
TSH rs4128956 131,848,063 9 3.6*10-05 0.355
TSH rs7865184 14,677,867 9 3.9*10-05 0.082 ZDHHC21
CysC rs563754 61,068,849 18 4.7*10-05 0.002
GFR rs2885618 41,244,839 18 4.8*10-05 1.0*10-04
TSH rs701801 100,166,859 10 5.8*10-05 0.090 HPS1
UAE rs33855 171,124,642 5 6.2*10-05 0.192
GFR rs10483741 61,059,454 14 6.3*10-05 0.298 PRKCH
CysC rs2121267 46,461,040 2 6.6*10-05 0.002 EPAS1
CysC rs1400306 83,256,163 11 7.2*10-05 0.061
TSH rs1223531 13,255,521 6 8.0*10-05 0.123 PHACTR1
CysC rs10504244 59,147,328 8 8.3*10-05 0.005
UAE rs2374688 106,175,669 12 9.1*10-05 0.087 BTBD11
UAE rs10519012 58,333,458 15 1.0*10-04 0.088
CysC rs1931619 82,682,388 6 1.0*10-04 0.05
UAE rs10501264 41,387,406 11 1.1*10-04 7.2*10-04
UAE rs10492025 111,735,770 12 1.1*10-04 0.41 RPH3A
UAE rs2056694 128,517,768 7 1.1*10-04 0.1
UAE rs8113386 16,332,871 19 1.1*10-04 0.053 KLF2
TSH rs295136 200,966,508 2 1.3 *10-04 0.64
2c. Magnitude and Location of Peak LOD scores for regions in which LOD exceeds 2.5.* Corresponding phenotype names on the web are 
PHOSPHORUSMV2 (serum phosphorous), URICACIDMV2 (uric acid), SCRLNMVNL6 (serum creatinine exam 6), LHMV3 (luteinizing hormone), 
GFRMVNL6 (GFR exam 6), CALCIUMMV2 (serum calcium), GFRMV7 (GFR exam 7), and SCRLNMVNL5 (serum creatinine exam 5)
Trait SNP Chromosome Physical 
location (Mb)
LOD 1.5 
(Lower; Mb)
LOD 1.5 
(Upper; Mb)
LOD
Serum Phosphorous rs754958 8 134307953 130413367 139409406 4.33
Uric acid rs10495487 2 2310945 107241 3787803 4.28
Serum creatinine (exam 6) rs10489578 1 229251990 224108350 230301885 3.35
Luteinizing Hormone rs10515134 17 52218447 45043525 59136652 3.17
GFR (exam 6) rs10489578 1 229251990 220881707 230301885 3.08
Serum Calcium rs10484370 6 18686366 10181754 21792915 3.03
GFR (exam 7) rs10511176 3 100809191 73551217 103238533 2.79
Serum creatinine (exam 5) rs10502302 18 2542886 156277 3857290 2.51
*All traits are multivariable-adjusted; see Table 1 for specific covariate adjustments.
Table 2: Most significant results for GFR (examination 7), UAE (examination 6), cysC (examination 7), and mean TSH (examinations 3 
and 4) by GEE (2a), FBAT (2b) and linkage (2c) analyses (Continued)BMC Medical Genetics 2007, 8(Suppl 1):S10 http://www.biomedcentral.com/1471-2350/8/S1/S10
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Table 3: SNPs showing the top 8 significant association with multiple measurements of GFR, UACR, or TSH phenotypes.* 
Corresponding phenotype names on the web are GFRMV7 (GFR), UAELNMV6 (UAE), and TSHMEAN34MV (TSH).
Trait chromosome SNP (rsID) Physical Location Genes (in or near) Mean p-value (GEE) Mean p-value (FBAT)
GFR 21 rs2839235 46625020 PCNT2 6.3*10-4 0.281
GFR 17 rs10512437 27046466 0.002 0.197
GFR 13 rs2480555 70785310 DACH1 0.003 0.006
GFR 7 rs10486135 11301740 0.004 0.142
GFR 7 rs727087 8244570 ICA1 0.004 0.223
GFR 13 rs1005066 70790573 DACH1 0.004 0.022
GFR 18 rs2885618 41244839 SETBP1 0.004 0.024
GFR 2 rs10496887 142198571 LRP1B 0.005 0.091
UAE 11 rs1712790 114126679 FAM55D 9.1*10-07 0.009
UAE 6 rs10485409 91562132 EPHA7 1.0*10-05 0.067
UAE 21 rs9305354 28397067 1.9*10-05 0.018
UAE 11 rs10502192 114127562 FAM55D 3.6*10-05 0.041
UAE 1 rs2077678 75246848 4.4*10-05 0.022
UAE 4 rs723464 133940196 4.9*10-05 0.000
UAE 21 rs9305355 28397088 5.0*10-05 0.011
UAE 6 rs10484587 143183270 AIG1 5.2*10-05 0.032
TSH 7 rs6977660 19578720 1.6*10-05 0.022
TSH 4 rs10493147 129095104 HSPA4L 2.1*10-05 0.019
TSH 7 rs10499559 21882699 DNAH11 2.8*10-05 0.111
TSH 6 rs9322817 105338926 7.4*10-05 0.576
TSH 2 rs9308765 118759439 INSIG2 7.7*10-05 0.404
TSH 6 rs6942231 105298507 1.6*10-04 0.541
TSH 7 rs10486365 19574604 1.9*10-04 0.221
TSH 7 rs10486653 34484903 BMPER 2.7*10-04 0.252
*see details in methods for criteria for generating mean p-value
Table 4: Results on Association Analysis for Candidate Genes
4a. Results of GEE analysis between SNPs in the CST3 and APOE candidate genes and the kidney function traits with p-value < 
0.05. Corresponding phenotype names on the web are CYSMV7 (CysC) and CKDMV7 (CKD).
Candidate 
gene
PHENOTYPE SNP CHROMOSO
ME
Location Minor allele 
frequency(%)
P_value 
(GEE)
Partial R2
CST3 CysC rs1158167 20 23,526,189 21 8.0 *10-9 2.5
CST3 CysC rs2145231 20 23,573,547 15 1.1*10-5 1.2
CST3 CysC rs726217 20 23,532,116 38 3.1*10-4 0.8
CST3 CysC rs911122 20 23,573,746 37 0.007 1.1
APOE CKD rs3760626 19 50,148,945 45 0.04 -
4b. Results of FBAT analysis between SNPs in the CST3 candidate gene and kidney function traits with p-value < 0.05. 
Corresponding phenotype names on the web are CYSMV7 (CysC) and UAEGE30HTNMV6 (UAE ≥ 30 mg/g)
Candidate 
gene
PHENOTYPE SNP CHROMOSO
ME
Location P-value
CST3 CysC rs1158167 20 23,526,189 0.006
CST3 CysC rs2145231 20 23,573,547 0.011
CST3 UAE ≥ 30* rs911122 20 23,573,746 0.032
*In a sample enriched for hypertensive individualsBMC Medical Genetics 2007, 8(Suppl 1):S10 http://www.biomedcentral.com/1471-2350/8/S1/S10
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also have excellent assessment of potential confounders
that we are able to adjust for in our residual creation.
Because the Framingham Heart Study has measured mul-
tiple traits, we are able to examine phenotype clustering.
Limitations exist as well. Kidney function was ascertained
by a single serum creatinine measure, which may lead to
misclassification. Our sample was not selected for CKD,
and as a result, affected individuals had moderate CKD as
reflected by the median eGFR of 53.7 ml/min/1.73 m2
among participants with CKD. The MDRD equation,
which was used to estimate GFR, has been shown to
underestimate GFR by 29% in healthy individuals [51];
therefore, we may have introduced additional misclassifi-
cation into our trait definition. We used a spot urine spec-
imen to assess UAE instead of a 24-hour collection.
However, spot UAE approximates 24-hour collections
[40], and are not prone to the error inherent in collecting
24-hour urine specimens. We used cysC as a continuous
trait and did not use transforming equations to estimate
GFR, as most existing equations have been developed in
small, selected samples [52,53], or developed using
immunoturbimetric method [53,54] instead of neph-
elometry and therefore we did not feel as though they
were appropriate for use in our large population-based
cohort. Further, we used cystatin C as a marker of kidney
function but can not rule out that it may also reflect cardi-
ovascular disease risk above and beyond its relation to
kidney function [55-59]. Our focus on multivariable
models may have led us to miss important bivariate asso-
ciations between SNPs and measures of kidney function.
Given that our findings have not yet been replicated,
many p-values may represent false positive findings. We
used TSH as an indicator of thyroid function, as we do not
have measures of free thyroxine or a reliable assessment of
thyroid disease in our study sample. Our sample is neither
ethnically diverse nor nationally representative, and it is
uncertain how our results would apply to other ethnic
groups. However, in genetics studies, sample homogene-
ity is beneficial in order to reduce population stratifica-
tion. For limitations pertaining to our genotyping or
statistical methods, please see the Overview [37].
Conclusion
Kidney function traits and TSH are associated with SNPs
on the Affymetrix 100K SNP GeneChip. Replication of
association between these traits and SNPs requires follow-
up in independent samples. These data will serve as a val-
uable resource for replication as more SNPs associated
with kidney function and endocrine traits are identified.
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